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Abstract
Introduction: Haemangiomas are vascular lesions resulting from abnormal proliferation of blood
vessels. They are the most common pediatric neoplasm. Kasabach-Merritt syndrome is a rare type
of vascular lesion with peculiar characteristics. The diagnosis is based upon three basic findings;
enlarging haemangioma, thrombocytopenia and consumption coagulopathy.
Case presentation: A 5 month old boy was admitted to the Pediatrics department for the
management of an abdominal wall mass. He was the first child of consanguineous parents, born in
a private hospital following uncomplicated pregnancy and delivery. At birth a bluish birth mark 5
cm × 5 cm was noted below the umbilicus. Over the next five months, this birth mark increased in
size and evolved into a swelling. As a result, the patient was admitted to Maternal and Child Health
(MCH) unit for the management of this swelling.
The clinical findings and imagining studies followed by laboratory investigations strongly suggested
the diagnosis of Kasabach-Merritt syndrome.
Vincristine was initiated after a trial of corticosteroids when the platelet count was 6000/cmm. One
week after the start of vincristine the size of the lesion started to decrease. At the end of 6th week
the lesion size decreased to half and the platelet count increased to 49,000/cmm. Vincristine was
continued for another 2 weeks, no further improvement in lesion size or platelet count was
observed. Vincristine was discontinued and the patient was shifted to the paediatric surgery
department. A fresh platelet transfusion was given and the haemangioma was excised completely.
The histopathological examination of the excised mass revealed a caverno-capillary haemangioma
with infiltration into skeletal muscles.
Conclusion: Six weeks treatment with vincristine in a dose of 0.5 mg/kg/week followed by surgical
excision may be the best management in selected cases of Kasabach-Merritt syndrome.
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Introduction
Haemangiomas are vascular lesions resulting from abnor-
mal proliferation of blood vessels. They are the most com-
mon pediatric neoplasm. They have a special importance
in clinical practice because of their distinct properties and
behavior. Some haemangiomas are very small and hardly
visible while others are large producing significant disfig-
urement [1]. The management of these lesions not only
depends upon their size and site but also on several other
distinct features as for Kasabach-Merritt syndrome, Klip-
pel-Trenaunay-Weber syndrome, Sturge-Weber syn-
drome, Rendu-Osler-Weber syndrome and von Hippel-
Lindau disease[1].
Kasabach-Merritt syndrome is a rare type of vascular
lesion with peculiar characteristics. The diagnosis is based
upon three basic findings; enlarging haemangioma,
thrombocytopenia and consumption coagulopathy. The
thrombocytopenia and consumption coagulopathy is
known as Kasabach-Merritt phenomenon [1]. It is argued
that exposure of subendothelial elements or abnormal
endothelium within the haemangioma results in aggrega-
tion and activation of platelets with a secondary con-
sumption of clotting factors [2]. If untreated, Kasabach-
Merritt syndrome can be life threatening with high mor-
tality. The present report describes a patient with Kasa-
bach-Merritt syndrome. The clinical presentation of the
case and outcome of selected treatment modalities are dis-
cussed in the light of previous studies done in connection
with this subject.
Case presentation
A 5 month old boy was admitted to the Paediatric depart-
ment for the management of an abdominal mass. He was
the first child of consanguineous parents, born in a private
hospital following uncomplicated pregnancy and deliv-
ery. At birth a bluish birth mark 5 cm × 5 cm was noted
below the umbilicus (figure 1). Over the next five months,
this birth mark increased in size and evolved into a swell-
ing so the patient was admitted in MCH for the manage-
ment of this swelling.
Initial examination in the paediatric ward showed a play-
ful child with normal development. His growth parame-
ters were well within normal limits. The abdomen was
distended below the umbilicus with obvious mass (12 cm
× 7 cm) involving both inguinal and hypogastric areas.
The mass was firm, non-tender, with indiscrete margins.
The overlying skin was reddish-blue and smooth with no
signs of inflammation. There was no visceromegaly. In
addition skin at other areas and mucus membranes was
normal. The examination of the central nervous system,
cardiovascular system, and respiratory system was unre-
markable.
The initial Complete Blood Count (CBC) showed a hae-
moglobin level of 10.6 gm %, a white cell count of 8000/
cmm, and a platelet count of 94,000/cmm. The relevant
haematological investigations carried out during 14 weeks
of the in-patient stay and thereafter in the out-patients'
department are shown in Table 1.
During the hospital stay, the liver function tests and urine
examination did not reveal any abnormality. An ultra-
sound of the abdomen showed a fluid collection in the
subcutaneous tissue and muscle planes of anterior
abdominal wall. Computed tomographic scan showed an
extensive heterogeneous soft tissue density mass suggest-
ing a haemangioma.
The above clinical findings and imagining studies fol-
lowed by laboratory investigations strongly suggested the
diagnosis of Kasabach-Merritt syndrome.
On day four of admission, the child developed mild pur-
puric rash. The haemotological parameters of the disease
were repeated (Table 1). The platelet count was found to
be 5000/cmm, haemoglobin level of 11.4 gm%, pro-
thrombin time more than 100 seconds, partial pro-
thrombin time more than 120 seconds and fibrinogen
level of 19.7 mg/dl. Platelet transfusion and fresh frozen
plasma were given and prednisolone was started at a dose
of 2 mg/kg/day in 3 divided doses. This therapy was con-
tinued for four weeks and then tapered off in another four
weeks period without any response. During this period
the patient received 4 units of platelet transfusions, 3 units
of packed red cell transfusions and 3 units of fresh frozen
plasma transfusions for supportive measures. The eight
weeks of steroid therapy resulted in the development of
cushanoid features. As the steroid was decreased in dose,
vincristine was instituted at dose of 0.5 mg/kg/week.
When vincristine was initiated the platelet count was
6000/cmm. One week after the start of vincristine the size
Reddish-blue lesion covering lower part of the abdomen  (caverno-capillary haemangioma) Figure 1
Reddish-blue lesion covering lower part of the abdomen 
(caverno-capillary haemangioma).Cases Journal 2008, 1:9 http://www.casesjournal.com/content/1/1/9
Page 3 of 4
(page number not for citation purposes)
of the lesion started to decrease. At the end of 6th week the
lesion size decreased to half and platelet count increased
to 49,000/cmm. Vincristine, in the same dose, was contin-
ued for another 2 weeks, no further improvement in
lesion size or platelet count was observed. Vincristine was
discontinued and the patient was shifted to the paediatric
surgery department. A fresh platelet transfusion was given
and the haemangioma was excised surgically completely
(figure 2). Two blood transfusions were given post-opera-
tively to correct the haemoglobin level and other blood
parameters. The histopathological examination of the
excised mass revealed a caverno-capillary haemangioma
with infiltration into skeletal muscles of the abdominal
wall. Two, four and six month follow-up after surgery
shows complete recovery with total correction of haemo-
tological parameters. (Table 1)
Discussion
Kasabach-Merritt syndrome shows wide variation in its
response to different treatment modalities. Currently,
there are no known treatment guidelines [3]. Different
interventions are recommended including compression,
embolization, use of interferon, use of steroids, laser ther-
apy, sclerotherapy, chemotherapy, radiation or surgery.
[1,2,4]. In each case the treating physician must decide the
most suitable treatment to achieve maximum involution
of the lesion and preservation of organ function.
Several researchers agree that most patients with Kasa-
bach-Merritt syndrome respond to steroids within a few
days of treatment [5]. However, one third will not
respond to conventional dose of prednisolone (2 mg/kg/
day) and mega dose 5 mg/kg/day may be effective. The
present patient did not respond to conventional dose of
steroid. Due to patient's condition the mega dose was not
used and the treatment was switched to vincristine.
The angiogenetic character of Kasabach-Merritt syndrome
indicates that chemotherapy is a logical treatment. Enjol-
ras and associates have reported that several steroid non-
responders show dramatic response to vincristine[6]. A
multicenter study in the United States also showed that
vincristine is a safe and effective treatment in the manage-
ment of Kasabach-Merritt syndrome [7]. However, it is
Abdominal lesion on day 7 postoperatively Figure 2
Abdominal lesion on day 7 postoperatively.
Table 1: Relevant haematological investigations carried out during hospital stay and follow-up at outpatients' department of MCH.
Hospital stay Investigations Treatment
WBC/cmm Hb gm % Platelet/cmm Others
1st day 8000 10.6 94000
4th day 11900 11.4 5000 PT > 100 sec (N = 28.8)
PTT > 120 sec (N = 34.8)
Fibrinogen = 19.7 mg/dl (N = 160–350)
Prednisolone
7th day 9300 9.0 4000
5th week 8200 9.7 6000 PT > 100 sec (N = 28.8)
PTT > 120 sec (N = 34.8)
Fibrinogen = 42.3 mg/dl (N = 160–350)
Vincristine
7th week 10400 10.2 19000
9th week 9500 9.8 45000
11th week 8500 10.7 49000
13th week 9500 11.2 50000 Surgery
4th month (OPD) 10200 10.9 278000 PT = 16.5 sec (N = 28.8)
PTT = 34.2 sec (N = 34.8)
Fibrinogen = 236 mg/dl (N = 160–350)
8th month (OPD) 5900 11.0 290000 PT = 16.2 sec (N = 28.8)
PTT = 27.8 sec (N = 34.8)
Fibrinogen = 251 mg/dl (N = 160–350)
OPD = Out patients' departmentCases Journal 2008, 1:9 http://www.casesjournal.com/content/1/1/9
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recommended that vincristine should be added when
other modalities are unsuccessful. In the present case the
vincristine was well tolerated but the response to this
treatment was partial.
Enjolras et al. found that the response rate to chemother-
apy was 100% with an average duration of treatment
being 22 weeks. In the present case it was not possible to
continue chemotherapy as the response became static
after 6 weeks. The potential side effects of vincristine such
as irritability, loss of deep tendon reflexes, and abdominal
pain were observed by Enjolras et al. but were not noted
in this case [6].
While monitoring the effects of above treatments, pred-
nisolone and vincristine, the outcome measures were an
increase in platelet count and fibrinogen level, and
decrease in tumor size. Similar parameters were also used
in other studies [7]. Haisley-Royster and co-workers have
reported that the increase in platelet count precedes the
regression in tumor size [7]. This phenomenon was also
observed in the present case.
Despite the risk of malignancy, radiation therapy is still
used for the treatment of Kasabach-Merritt syndrome [8].
Other researchers recommend the use of interferon alpha
when steroid treatment fails [9]. Some researchers have
used combinations of two or more treatment modalities
[5], while other investigators recommend a stepwise mul-
timodal approach for the treatment of this disease entity
[10,11].
A major mainstay of the treatment of Kasabach-Merritt
syndrome is surgical excision. This approach is recom-
mended for single cutaneous lesions or multiple lesions
in the spleen (splenectomy) or liver (wedge resection/
hepatectomy) [2,12,13]. This is the only treatment that
provides cure in significant number of cases. However,
before each surgical intervention the patient must be sta-
bilized. In the present case the administration of vincris-
tine helped to stabilize the patient's general condition
which was not possible with sole and repeated adminis-
trations of platelets and fresh frozen plasma.
Conclusion
Six weeks treatment with vincristine in a dose of 0.5 mg/
kg/week followed by surgical excision may be the best
management in selected cases of Kasabach-Merritt syn-
drome.
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